Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.64 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.64 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | RARB | P10826 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butibufen SCHEMBL24177 | 0.98 | PTGS1 (0.73) | PTGS1PTGS2ALOX5LMNACYP2C9 | |
| Butibufen SCHEMBL7346774 | 0.98 | PTGS1 (0.73) | PTGS1PTGS2ALOX5LMNACYP2C9 | |
| SCHEMBL10443322 | 0.85 | PTGS1 (0.59) | PTGS1PTGS2ALOX5LMNACYP2C9 | |
| SCHEMBL27934588 | 0.85 | PTGS1 (0.69) | PTGS1PTGS2ALOX5LMNACYP2C9 | |
| SCHEMBL12608939 | 0.84 | ESR1 (0.59) | PTGS1PTGS2ALOX5LMNACYP2C9 | |
| Butibufen SCHEMBL11729847 | 0.83 | PTGS1 (0.55) | PTGS1PTGS2ALOX5LMNACYP2C9 | |
| SCHEMBL1574429 | 0.83 | AKR1C3 (0.58) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL9474541 | 0.83 | PTGS1 (0.71) | PTGS1PTGS2ALOX5LMNACYP2C9 | |
| SCHEMBL11185943 | 0.83 | PTGS1 (0.57) | PTGS1PTGS2ALOX5LMNACYP2C9 | |
| SCHEMBL8813286 | 0.83 | PTGS1 (0.71) | PTGS1PTGS2ALOX5LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6929805-B2 | For oral administration comprising an analgesic with rapid onset of action and at least one systemically acting analgesic with sustained action, such as a combination of benzocaine and acetylsalicylic acid (ASA) | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-16 | — | — | US | claimed |
| US-10716795-B2 | Steroid analogues for neuroprotection | EMORY UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITY DE STRASBOURG (FR) | 2019-03-26 | — | — | US | disclosed |
| US-20180221390-A1 | Steroid Analogues for Neuroprotection | UNIV EMORY (US) | 2018-08-09 | — | — | US | disclosed |
| US-9675696-B2 | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain | WARSAW ORTHOPEDIC, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170065615-A1 | Steroid Analogues for Neuroprotection | UNIV EMORY (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527881-B2 | Steroid analogues for neuroprotection | EMORY UNIVERSITY (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2242359-B1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIV STRASBOURG (FR) | 2016-06-01 | — | — | EP | disclosed |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2016-03-17 | — | — | US | disclosed |
| US-9051302-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | UNIVERSITE DE STRASBOURG (FR) | 2015-06-09 | — | — | US | disclosed |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS PHARMACEUTICALS, INC. | 2003-12-25 | — | — | US | disclosed |
| US-20030232877-A1 | 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | CRABTREE ACQUISITION CO, LLC | 2003-12-18 | — | — | US | disclosed |
| US-6608101-B1 | Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; | ATHEROGENICS, INC. | 2003-08-19 | — | — | US | disclosed |
| EP-1330459-A2 | TRIPTOLIDE ANALOGS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | EMORY UNIVERSITY (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1330448-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | Atherogenics, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053359-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPYN-1-ONES AND THEIR USE TO TREAT DISORDERS | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030027806-A1 | Triptolide analogs for the treatment of autoimmune and inflammatory disorders | EMORY UNIVERSITY | 2003-02-06 | — | — | US | disclosed |
| WO-2002028862-A2 | TRIPTOLIDE ANALOGS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | EMORY UNIVERSITY (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232877-A1 | 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | SLC10A1, PKD1, ABCB11 | PTGS1 390/4885PTGS2 1126/4885ALOX5 1772/4885 |
| US-20180221390-A1 | Steroid Analogues for Neuroprotection | CYP11A1, NR3C2, HSD17B7 | PTGS1 203/4885PTGS2 511/4885ALOX5 251/4885 |
| US-20030027806-A1 | Triptolide analogs for the treatment of autoimmune and inflammatory disorders | SSB, ENPP2, NOD1 | PTGS1 77/4885PTGS2 250/4885ALOX5 217/4885 |
| US-10239856-B2 | Synthesis of resorcylic acid lactones useful as therapeutic agents | HSP90AA1, HSP90AB1, HSP90AB2P | PTGS1 798/4885PTGS2 904/4885ALOX5 2871/4885 |
| US-10716795-B2 | Steroid analogues for neuroprotection | CYP11A1, NR3C2, HSD17B7 | PTGS1 203/4885PTGS2 511/4885ALOX5 251/4885 |
| US-20170065615-A1 | Steroid Analogues for Neuroprotection | CYP11A1, NR3C2, HSD17B7 | PTGS1 203/4885PTGS2 511/4885ALOX5 251/4885 |
| US-20030236298-A1 | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | VCAM1, ICAM1, ITGB1 | PTGS1 35/4885PTGS2 217/4885ALOX5 606/4885 |
| US-20160075677-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | HSP90AA1, HSP90AB1, HSP90AB2P | PTGS1 798/4885PTGS2 904/4885ALOX5 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.